Certified by Founder Lodge
ARTBIO
United States - Cambridge, Massachusetts
START UP
1 Disclosed Funding Rounds $90,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| December, 08 ,2023 | Series A | $90,000,000 | |
| July, 30 ,2025 | Series B | $132,000,000.00 |
Third Rock Ventures
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
FOVC | $2,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Project Eleven | $20,000,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)
